Horizon Pharma's SkyeParma: USPTO issues notice of allowance for RAYOS tablets Horizon Pharma announced that SkyePharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 2012/0177734 entitled "Delayed Release Tablet with Defined Core Geometry" that covers the U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to issue from this application will expire in 2024 for the U.S. patent. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Horizon CEO Timothy P. Walbert commented: "This patent allowance is a critical expansion of the patent estate for RAYOS. We are focused on protecting the commercial potential of RAYOS to 2024 and we will begin the RAYOS commercial launch this quarter."
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.